1
|
Baqar S, Bonavia A, Louis Bourgeois A, Campo JJ, Clifford A, Hanevik K, Hasso-Agopsowicz M, Hausdorff W, Kaminski R, MacLennan CA, Mantis N, Martin LB, Omore R, Pasetti M, Pavlinac P, Phalipon A, Poly F, Porter C, Ramasamy MN, Rogawski McQuade ET, Sztein MB, Walker R. The 2022 Vaccines Against Shigella and Enterotoxigenic Escherichia coli (VASE) Conference: Summary of breakout workshops. Vaccine 2024; 42:1445-1453. [PMID: 38036392 PMCID: PMC10953702 DOI: 10.1016/j.vaccine.2023.11.045] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2023] [Revised: 08/25/2023] [Accepted: 11/21/2023] [Indexed: 12/02/2023]
Abstract
The global public health nonprofit organization PATH hosted the third Vaccines Against Shigella and Enterotoxigenic Escherichia coli (VASE) Conference in Washington, DC, from November 29 to December 1, 2022. This international gathering focused on cutting-edge research related to the development of vaccines against neglected diarrheal pathogens including Shigella, enterotoxigenic Escherichia coli (ETEC), Campylobacter, and non-typhoidal Salmonella. In addition to the conference's plenary content, the agenda featured ten breakout workshops on topics of importance to the enteric vaccine field. This unique aspect of VASE Conferences allows focused groups of attendees to engage in in-depth discussions on subjects of interest to the enteric vaccine development community. In 2022, the workshops covered a range of topics. Two focused on the public health value of enteric vaccines, with one examining how to translate evidence into policy and the other on the value proposition of potential combination vaccines against bacterial enteric pathogens. Two more workshops explored new tools for the development and evaluation of vaccines, with the first on integrating antigen/antibody technologies for mucosal vaccine and immunoprophylactic development, and the second on adjuvants specifically for Shigella vaccines for children in low- and middle-income countries. Another pair of workshops covered the status of vaccines against two emerging enteric pathogens, Campylobacter and invasive non-typhoidal Salmonella. The remaining four workshops examined the assessment of vaccine impact on acute and long-term morbidity. These included discussions on the nature and severity of intestinal inflammation; cellular immunity and immunological memory in ETEC and Shigella infections; clinical and microbiologic endpoints for Shigella vaccine efficacy studies in children; and intricacies of protective immunity to enteric pathogens. This article provides a brief summary of the presentations and discussions at each workshop in order to share these sessions with the broader enteric vaccine field.
Collapse
Affiliation(s)
| | - Aurelio Bonavia
- Bill & Melinda Gates Medical Research Institute, United States
| | | | | | | | - Kurt Hanevik
- University of Bergen, Norway; Norwegian National Advisory Unit for Tropical Infectious Diseases, Medical Department, Haukeland University Hospital, Norway
| | | | - William Hausdorff
- PATH, United States; Faculty of Medicine, Université Libre de Bruxelles, Belgium
| | | | - Calman A MacLennan
- Enteric and Diarrheal Diseases, Bill & Melinda Gates Foundation, United Kingdom; The Jenner Institute, United Kingdom
| | - Nicholas Mantis
- Wadsworth Center, New York State Department of Health, United States
| | | | - Richard Omore
- Kenya Medical Research Institute Center for Global Health Research, Kenya
| | | | | | | | | | - Chad Porter
- Naval Medical Research Command, United States
| | | | | | | | | |
Collapse
|
2
|
Cardemil CV, Cao Y, Posavad CM, Badell ML, Bunge K, Mulligan MJ, Parameswaran L, Olson-Chen C, Novak RM, Brady RC, DeFranco E, Gerber JS, Pasetti M, Shriver M, Coler R, Berube B, Suthar MS, Moreno A, Gao F, Richardson BA, Beigi R, Brown E, Neuzil KM, Munoz FM. Maternal COVID-19 Vaccination and Prevention of Symptomatic Infection in Infants. Pediatrics 2024; 153:e2023064252. [PMID: 38332733 PMCID: PMC10904887 DOI: 10.1542/peds.2023-064252] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 12/13/2023] [Indexed: 02/10/2024] Open
Abstract
BACKGROUND AND OBJECTIVES Maternal vaccination may prevent infant coronavirus disease 2019 (COVID-19). We aimed to quantify protection against infection from maternally derived vaccine-induced antibodies in the first 6 months of an infant's life. METHODS Infants born to mothers vaccinated during pregnancy with 2 or 3 doses of a messenger RNA COVID-19 vaccine (nonboosted or boosted, respectively) had full-length spike (Spike) immunoglobulin G (IgG), pseudovirus 614D, and live virus D614G, and omicron BA.1 and BA.5 neutralizing antibody (nAb) titers measured at delivery. Infant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection was determined by verified maternal-report and laboratory confirmation through prospective follow-up to 6 months of age between December 2021 and July 2022. The risk reduction for infection by dose group and antibody titer level was estimated in separate models. RESULTS Infants of boosted mothers (n = 204) had significantly higher Spike IgG, pseudovirus, and live nAb titers at delivery than infants of nonboosted mothers (n = 271), and were 56% less likely to acquire infection in the first 6 months (P = .03). Irrespective of boost, for each 10-fold increase in Spike IgG titer at delivery, the infant's risk of acquiring infection was reduced by 47% (95% confidence interval 8%-70%; P = .02). Similarly, a 10-fold increase in pseudovirus titers against Wuhan Spike, and live virus nAb titers against D614G, and omicron BA.1 and BA.5 at delivery were associated with a 30%, 46%, 56%, and 60% risk reduction, respectively. CONCLUSIONS Higher transplacental binding and nAb titers substantially reduced the risk of SARS-CoV-2 infection in infants, and a booster dose amplified protection during a period of omicron predominance. Until infants are age-eligible for vaccination, maternal vaccination provides passive protection against symptomatic infection during early infancy.
Collapse
Affiliation(s)
- Cristina V. Cardemil
- National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland
| | - Yi Cao
- Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington
| | - Christine M. Posavad
- Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington
| | - Martina L. Badell
- Division of Maternal Fetal Medicine, Department of Gynecology and Obstetrics, Emory University Hospital Midtown Perinatal Center, Atlanta, Georgia
| | - Katherine Bunge
- Department of Obstetrics, Gynecology, and Reproductive Sciences, Magee-Women’s Hospital, Pittsburgh, Pennsylvania
| | - Mark J. Mulligan
- New York University Langone Vaccine Center, and Division of Infectious Diseases and Immunology, Department of Medicine, New York University Grossman School of Medicine, New York, New York
| | - Lalitha Parameswaran
- New York University Langone Vaccine Center, and Division of Infectious Diseases and Immunology, Department of Medicine, New York University Grossman School of Medicine, New York, New York
| | - Courtney Olson-Chen
- Department of Obstetrics and Gynecology, University of Rochester, Rochester, New York
| | - Richard M. Novak
- Division of Infectious Diseases, University of Illinois, Chicago, Illinois
| | - Rebecca C. Brady
- Division of Infectious Diseases, Cincinnati Children’s Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio
| | - Emily DeFranco
- Division of Infectious Diseases, Cincinnati Children’s Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio
| | - Jeffrey S. Gerber
- Division of Infectious Diseases, Children’s Hospital of Philadelphia, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania
| | - Marcela Pasetti
- Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland
| | - Mallory Shriver
- Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland
| | - Rhea Coler
- Seattle Children’s Research Institute, Center for Global Infectious Disease Research, Seattle, Washington
| | - Bryan Berube
- Seattle Children’s Research Institute, Center for Global Infectious Disease Research, Seattle, Washington
| | - Mehul S. Suthar
- Emory Vaccine Center, Emory School of Medicine, Emory University, Atlanta, Georgia
| | - Alberto Moreno
- Emory Vaccine Center, Emory School of Medicine, Emory University, Atlanta, Georgia
| | - Fei Gao
- Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington
| | - Barbra A. Richardson
- Departments of Biostatistics and Global Health, University of Washington, Divisions of Vaccine and Infectious Disease and Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington
| | - Richard Beigi
- Department of Obstetrics, Gynecology, and Reproductive Sciences, Magee-Women’s Hospital, Pittsburgh, Pennsylvania
| | - Elizabeth Brown
- Departments of Biostatistics and Global Health, University of Washington, Divisions of Vaccine and Infectious Disease and Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington
| | - Kathleen M. Neuzil
- Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland
| | - Flor M. Munoz
- Departments of Pediatrics and Molecular Virology & Microbiology, Baylor College of Medicine, and Texas Children’s Hospital, Houston, Texas
| | | |
Collapse
|
3
|
Cicchetti A, Mangili P, Fodor A, Mori M, Chiara A, Deantoni C, Pasetti M, Palazzo G, Ubeira Gabellini MG, Rancati T, Del Vecchio A, Muzio NGD, Fiorino C. Dosimetry Predictors of Late Skin Reactions after Whole Breast Radiotherapy on a Large Mono-Institutional Cohort of Patients. Int J Radiat Oncol Biol Phys 2023; 117:e171. [PMID: 37784780 DOI: 10.1016/j.ijrobp.2023.06.1012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) To develop an NTCP model predicting late skin toxicity using dosimetric parameters from the breast dermis to identify possible RT constraints on such a structure. MATERIALS/METHODS The skin structure was defined as the 5 mm inner isotropic expansion from the outer CT body contour. It was retrospectively segmented on a large mono-Institutional cohort of early-stage breast cancer patients enrolled between 2009 and 2017 (n = 1066). Patients were treated with tangential-field RT, delivering 40 Gy in 15 fractions without a RT boost. Toxicity was reported during FU using SOMA/LENT scoring. The study endpoint was moderate-severe late toxicity consisting of Fibrosis-Atrophy-Telangiectasia-Pain (FATP G2+) developed within 42 months after RT completion. Automatic delineation of skin and DVH extraction were accomplished by scripting using the MIM_assistant software. Also, the impact of changes in the dose calculation algorithms during enrolment time was quantified. A logistic model was created by combining multifactorial variables, considering both clinical factors and the absolute skin DVH (cc). Variance Inflation Factor (VIF) was performed to reduce the multicollinearity. Repeated 5-fold cross-validation with SMOTE approach to overcome the class unbalance was applied for model feature selection. The predictive model was then developed on the entire population due to the limited G2+ events. RESULTS The FATP G2+ rate was 3.8% with 40/1066 experiencing late toxicity. Among them, a 40% had already developed acute symptoms after RT completion showing a consequential effect. The multicollinearity analysis selected 27 clinical-treatment-dosimetric factors. After repeated (20 times) 5-fold cross-validation, the best-performing model included Post-Surgery Cosmetic alterations, Aromatase Inhibitors (as a protective factor), V20 Gy (50% of the prescribed dose - DVH plateau region) and V42 Gy (105% of the prescribed dose - DVH high-dose tail). Accuracy and f1-score were 0.76 and 0.58 in both training and test sets, providing good reliability for selected variables. AUC for the final model on the entire population was 0.76+/-0.04. CONCLUSION We quantified the association between fibrosis and skin DVH when delivering 40 Gy in 15fr. The model suggested an independent role of V20 and V42 Gy and a heavy risk modulation by surgical effects and aromatase inhibitors. This last factor could interfere with adipose tissue and water-content distribution within the breast. For this purpose, a CT-based densitometry characterization of toxicity patients is ongoing.
Collapse
Affiliation(s)
- A Cicchetti
- Fondazione IRCCS Istituto Nazionale dei Tumori, Data Science Unit, Milan, Italy
| | - P Mangili
- San Raffaele Scientific Institute, Milan, Italy
| | - A Fodor
- Department of Radiation Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - M Mori
- San Raffaele Scientific Institute - IRCCS, Milano, Italy
| | - A Chiara
- San Raffaele Scientific Institute, Milan, Italy
| | - C Deantoni
- San Raffaele Scientific Institute, Milan, Italy
| | - M Pasetti
- San Raffaele Scientific Institute, Milano, Italy
| | - G Palazzo
- San Raffaele Scientific Institute, Milan, Italy
| | | | - T Rancati
- Fondazione IRCCS Istituto Nazionale dei Tumori, Data Science Unit, Milan, Italy
| | | | - N G Di Muzio
- Department of Radiation Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - C Fiorino
- San Raffaele Scientific Institute - IRCCS, Milano, Italy
| |
Collapse
|
4
|
Nuccio A, Torrisi M, Ogliari F, Giannini L, Pasetti M, Fodor A, Gigliotti C, Fiorino C, Arcangeli S, Bulotta A, Dell'Oca I, Cascinu S, Di Muzio N. 105P Thoracic radiotherapy and tyrosine kinase inhibitors association: Results from a monoinstitutional experience. ESMO Open 2023. [DOI: 10.1016/j.esmoop.2023.100963] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/05/2023] Open
|
5
|
Munoz FM, Posavad CM, Richardson BA, Badell ML, Bunge K, Mulligan MJ, Parameswaran L, Kelly C, Olsen-Chen C, Novak RM, Brady RC, Pasetti M, DeFranco E, Gerber JS, Shriver M, Suthar MS, Moore K, Coler R, Berube B, Kim SH, Piper JM, Miller A, Cardemil C, Neuzil KM, Beigi R. COVID-19 booster vaccination during pregnancy enhances maternal binding and neutralizing antibody responses and transplacental antibody transfer to the newborn (DMID 21-0004). medRxiv 2022:2022.06.13.22276354. [PMID: 35734087 PMCID: PMC9216723 DOI: 10.1101/2022.06.13.22276354] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Abstract
IMPORTANCE COVID-19 vaccination is recommended during pregnancy for the protection of the mother. Little is known about the immune response to booster vaccinations during pregnancy. OBJECTIVE To measure immune responses to COVID-19 primary and booster mRNA vaccination during pregnancy and transplacental antibody transfer to the newborn. DESIGN Prospective cohort study of pregnant participants enrolled from July 2021 to January 2022, with follow up through and up to 12 months after delivery. SETTING Multicenter study conducted at 9 academic sites. PARTICIPANTS Pregnant participants who received COVID-19 vaccination during pregnancy and their newborns. EXPOSURES Primary or booster COVID-19 mRNA vaccination during pregnancy. MAIN OUTCOMES AND MEASURES SARS-CoV-2 binding and neutralizing antibody (nAb) titers after primary or booster COVID-19 mRNA vaccination during pregnancy and antibody transfer to the newborn. Immune responses were compared between primary and booster vaccine recipients in maternal sera at delivery and in cord blood, after adjusting for days since last vaccination. RESULTS In this interim analysis, 167 participants received a primary 2-dose series and 73 received a booster dose of mRNA vaccine during pregnancy. Booster vaccination resulted in significantly higher binding and nAb titers, including to the Omicron BA.1 variant, in maternal serum at delivery and cord blood compared to a primary 2-dose series (range 0.55 to 0.88 log 10 higher, p<0.0001 for all comparisons). Although levels were significantly lower than to the prototypical D614G variant, nAb to Omicron were present at delivery in 9% (GMT ID50 12.7) of Pfizer and 22% (GMT ID50 14.7) of Moderna recipients, and in 73% (GMT ID50 60.2) of boosted participants (p<0.0001). Transplacental antibody transfer was efficient regardless of vaccination regimen (median transfer ratio range: 1.55-1.77 for binding IgG and 1.00-1.78 for nAb). CONCLUSIONS AND RELEVANCE COVID-19 mRNA vaccination during pregnancy elicited robust immune responses in mothers and efficient transplacental antibody transfer to the newborn. A booster dose during pregnancy significantly increased maternal and cord blood antibody levels, including against Omicron.Findings support continued use of COVID-19 vaccines during pregnancy, including booster doses. TRIAL REGISTRATION clinical trials.gov; Registration Number: NCT05031468 ; https://clinicaltrials.gov/ct2/show/NCT05031468. KEY POINTS Question: What is the immune response after COVID-19 booster vaccination during pregnancy and how does receipt of a booster dose impact transplacental antibody transfer to the newborn?Findings: Receipt of COVID-19 mRNA vaccines during pregnancy elicited robust binding and neutralizing antibody responses in the mother and in the newborn. Booster vaccination during pregnancy elicited significantly higher antibody levels in mothers at delivery and cord blood than 2-dose vaccination, including against the Omicron BA.1 variant.Meaning: COVID-19 vaccines, especially booster doses, should continue to be strongly recommended during pregnancy.
Collapse
|
6
|
deantoni C, Chiara A, Mirabile A, Broggi S, Fiorino C, Fodor A, Pasetti M, Tummineri R, Zerbetto F, Baroni S, Sanchez Galvan A, Gregorc V, Dell'Oca I, Di Muzio N. PO-1100 Impact of sarcopenia in oropharyngeal cancer patients treated with radical chemo-radiotherapy. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)03064-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
7
|
Esposito P, Castriconi R, Mangili P, Broggi S, Fodor A, Pasetti M, Tudda A, Di Muzio N, del Vecchio A, Fiorino C. MO-0790 Knowledge-Based automatic plan optimization for left-sided whole breast tomotherapy. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)02426-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
8
|
Tummineri R, Fodor A, Zerbetto F, Pasetti M, Deantoni C, Sanchez Galvan A, Castriconi R, Mangili P, Del Vecchio A, Di Muzio N. PO-1177 Acute toxicity of hypofractionated locoregional radiotherapy in advanced breast cancer. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)03141-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
9
|
Baroni S, Gulletta S, Pasetti M, Vergara P, Broggi S, Tummineri R, Deantoni C, Zerbetto F, Fodor A, Mandurino G, Sanchez Galvan A, Fierro N, Dell'Oca I, Arcangeli S, Di Muzio N. MO-0717 Radiation Therapy and Cardiovascular Implanted Electronic Devices: a single center years expierence. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)02415-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
10
|
Castriconi R, Esposito P, Mangili P, Pasetti M, Fodor A, Di Muzio N, del Vecchio A, Fiorino C. Knowledge-based (KB) automatic plan optimization can replace manual planning in tangential field irradiation for right breast cancer radiotherapy. Phys Med 2021. [DOI: 10.1016/s1120-1797(22)00128-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
11
|
Fodor A, Brombin C, Mangili P, Pasetti M, Tummineri R, Longobardi B, Zerbetto F, Castriconi R, Esposito P, Broggi S, Dell’Oca I, Deantoni C, Sanchez Galvan A, Perna L, Deli A, Chiara A, Rancoita P, Fiorino C, Del Vecchio A, Di Serio M, Di Muzio N. PO-1139 Skin toxicity in 1325 breast cancer patients treated with hypofractionated RT without boost. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)07590-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
12
|
Esposito P, Castriconi R, Mangili P, Broggi S, Fodor A, Longobardi B, Pasetti M, Perna L, Di Muzio N, Del Vecchio A, Fiorino C. OC-0468 Implementation of a Knowledge-Based automated approach for whole breast tangential field planning. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)06917-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
13
|
Fodor A, Deantoni C, Tummineri R, Fiorino C, Dell’Oca I, Mori M, Broggi S, Pasetti M, Perna L, Villa S, Mandurino G, Sanchez Galvan A, Baroni S, Pacifico P, Del Vecchio A, Di Muzio N. PO-1189 Stereotactic radiotherapy for lung oligometastases from colorectal cancer. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)07640-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
14
|
Zerbetto F, Foti S, Deantoni C, Pasetti M, Chiara A, Roberta T, Broggi S, Di Muzio N. PO-1401 Lung metastasis from renal cell carcinoma: SBRT alone or in association with target therapy as a potential treatment option. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)07852-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
15
|
Di Muzio N, Deantoni C, Cozzarini C, Dell'Oca I, Zerbetto F, Mangili P, Broggi S, Pasetti M, Chiara A, Borroni F, Tummineri R, Perna L, Calandrino R, Fiorino C, Fodor A. PO-1173: Long term results of IG-IMRT in high risk prostate cancer patients: a monoinstitutional experience. Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)01191-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
16
|
Fodor A, Mangili P, Brombin C, Zerbetto F, Longobardi B, Borroni F, Tummineri R, Pasetti M, Rancoita P, Perna L, Dell'Oca I, Deantoni C, Esposito P, Deli A, Rossi E, Chiara A, Broggi S, Slim N, Passoni P, Cattaneo M, Bolognesi A, Fiorino C, Di Serio M, Di Muzio N. PO-0955: Molecular subtypes and local control in 1054 breast cancer patients treated with de-escalated 3DCRT. Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)00973-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
17
|
Esposito P, Castriconi R, Mangili P, Fodor A, Pasetti M, Di Muzio N, Fiorino C, Calandrino R. PD-0301: Virtual Tangential Arc Therapy (ViTAT): toward large scale auto-planning for breast cancer treatment. Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)00325-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
18
|
Tummineri R, Fodor A, Borroni F, Zerbetto F, Deantoni C, Deli A, Slim N, Pasetti M, Broggi S, Fiorino C, Di Muzio N. PO-0879: Stereotactic radiotherapy for re-irradiation of relapsed intracranic lesions. Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)00896-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
19
|
Zerbetto F, Deantoni C, Borroni F, Tummineri R, Fodor A, Pasetti M, Chiara A, Broggi S, Longobardi B, Perna L, Fiorino C, Di Muzio N. PO-1246: Stereotactic Body Radiotherapy For Bone Metastases In Oligometastatic-Oligoprogressive Patients. Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)01264-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
20
|
Chiara A, Broggi S, Salvadori G, Peccatori J, Assanelli A, Piemontese S, Pasetti M, Selli S, Calandrino R, Ciceri F, Fiorino C, Di Muzio N. PO-0915: Clinical Activation Of An Efficient Low-Dose Total Body Irradiation Using The Tomodirect Approach. Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)00932-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
21
|
Edelman R, Deming ME, Toapanta FR, Heuser MD, Chrisley L, Barnes RS, Wasserman SS, Blackwelder WC, Handwerger BS, Pasetti M, Siddiqui KM, Sztein MB. The SENIEUR protocol and the efficacy of hepatitis B vaccination in healthy elderly persons by age, gender, and vaccine route. Immun Ageing 2020; 17:9. [PMID: 32355503 PMCID: PMC7187507 DOI: 10.1186/s12979-020-00179-9] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2019] [Accepted: 03/31/2020] [Indexed: 01/27/2023]
Abstract
BACKGROUND Reduced response to hepatitis B vaccines is associated with aging, confounding and comorbid conditions, as well as inadvertent subcutaneous (SC) inoculation. We hypothesized that the antibody and T cell-mediated immune responses (T-CMI) of elderly adults to a vaccine intended for intramuscular (IM) administration would be attenuated when deposited into SC fat, independent of confounding conditions. RESULTS Fifty-two healthy, community dwelling elderly adults (65-82 years), seronegative for HBV, were enrolled in the SENIEUR protocol as a strictly healthy population. These seniors were randomized to receive a licensed alum-adjuvanted recombinant HBV vaccine either SC or IM, with the inoculum site verified by imaging. The response rates, defined as hepatitis B surface antibodies (HBsAb) ≥10 IU/L, were significantly lower in the elderly than in young adults, a group of 12, healthy, 21-34-year-old volunteers. Moreover, elderly participants who received the vaccine IM were significantly more likely to be responders than those immunized SC (54% versus 16%, p = 0.008). The low seroconversion rate in the IM group progressively declined with increasing age, and responders had significantly lower HBsAb titers and limited isotype responses. Moreover, T-CMI (proliferation and cytokine production) were significantly reduced in both percentage of responders and intensity of the response for both Th1 and Th2 subsets in the elderly. CONCLUSIONS Our data demonstrate the blunted immunogenicity of SC inoculation as measured by peak titers and response rates. Further, the qualitative and quantitative deficits in B- and T-CMI responses to primary alum adjuvanted protein antigens persisted even in strictly healthy elderly populations with verified IM placement compared to younger populations. CLINICAL TRIAL REGISTRATION ClinicalTrials.gov, NCT04162223. Registered 14 November 2019. Retrospectively registered.
Collapse
Affiliation(s)
- Robert Edelman
- Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, USA
- Department of Medicine, University of Maryland School of Medicine, Baltimore, USA
| | - Meagan E. Deming
- Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, USA
- Department of Medicine, University of Maryland School of Medicine, Baltimore, USA
- Institute of Human Virology, University of Maryland School of Medicine, Baltimore, USA
| | - Franklin R. Toapanta
- Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, USA
- Department of Medicine, University of Maryland School of Medicine, Baltimore, USA
| | - Mark D. Heuser
- Department of Medicine, University of Maryland School of Medicine, Baltimore, USA
- Present Adress: Department of Veterans Affairs, Salisbury VA Health Care System, Salisbury, NC USA
| | - Lisa Chrisley
- Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, USA
| | - Robin S. Barnes
- Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, USA
| | - Steven S. Wasserman
- Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, USA
- Department of Medicine, University of Maryland School of Medicine, Baltimore, USA
- Present Adress: Office of Research, University of Virginia, Charlottesville, USA
| | - William C. Blackwelder
- Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, USA
| | - Barry S. Handwerger
- Rheumatology and Clinical Immunology, Dept of Medicine, University of Maryland School of Medicine, Baltimore, USA
| | - Marcela Pasetti
- Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, USA
- Department of Pediatrics, University of Maryland School of Medicine, Baltimore, USA
- Department of Microbiology and Immunology, Dept of Medicine, University of Maryland School of Medicine, Baltimore, USA
| | - Khan M. Siddiqui
- Imaging Informatics and Body Magnetic Resonance Imaging unit, Veterans Affairs Maryland Health Care System Baltimore, Baltimore, MD USA
- Present Adress: Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, USA
| | - Marcelo B. Sztein
- Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, USA
- Department of Medicine, University of Maryland School of Medicine, Baltimore, USA
- Department of Pediatrics, University of Maryland School of Medicine, Baltimore, USA
- Department of Microbiology and Immunology, Dept of Medicine, University of Maryland School of Medicine, Baltimore, USA
| |
Collapse
|
22
|
Chiara A, Broggi S, Pasetti M, Dell'oca I, Azizi M, Salvadori G, Selli S, Marcatti M, Assanelli A, Peccatori J, Cattaneo M, Ciceri F, Di Muzio N. PO-0868 Total Marrow Irradiation in Myeloma Multiple patients candidate to allogeneic transplant. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)31288-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
23
|
Mangili P, Mori M, Fodor A, Longobardi B, Signorotto P, Pasetti M, Zerbetto F, Di Muzio N, Calandrino R, Fiorino C. EP-1993 Evidence of CTV underdosing due to anatomical changes during breast Helical Tomotherapy. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)32413-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
24
|
Tucker S, Kim L, Liebowitz D, Lin K, Kasparek K, Nazareno J, Gottlieb K, Pasetti M. Oral immunization of a rAd vector expressing norovirus VP1 elicits a potent mucosal immune response without an increase in anti-vector immunity. Int J Infect Dis 2018. [DOI: 10.1016/j.ijid.2018.04.3583] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
25
|
Fodor A, Broggi S, Incerti E, Dell'Oca I, Fiorino C, Samanes Gajate A, Passoni P, Pasetti M, Cattaneo M, Gianolli L, Calandrino R, Picchio M, Di Muzio N. EP-1390: Salvage (postponed) hypofractionated tomotherapy for progressive MPM in patients with intact lungs. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)31699-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
26
|
Cozzarini C, Noris Chiorda B, Fiorino C, Pasetti M, Briganti A, Deantoni C, Deli A, Fodor A, Fossati N, Gandaglia G, Sini C, Montorsi F, Di Muzio N. PO-0730: The independent benefit deriving from high doses and WPRT in salvage post-prostatectomy radiotherapy. Radiother Oncol 2017. [DOI: 10.1016/s0167-8140(17)31167-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
27
|
Di Muzio N, Fodor A, Deantoni C, Noris Chiorda B, Broggi S, Mangili P, Dell'Oca I, Chiara A, Passoni P, Slim N, Pasetti M, Calandrino R, Cozzarini C, Fiorino C. EP-1318: Is hypofractionation combined to WPRT effective in high risk prostate cancer patients? Radiother Oncol 2017. [DOI: 10.1016/s0167-8140(17)31753-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
28
|
Pasetti M, Fodor A, Sini C, Zerbetto F, Mangili P, Signorotto P, Dell’Oca I, Gumina C, Azizi M, Deli A, Passoni P, Slim N, Deantoni C, Noris Chiorda B, Foti S, Chiara A, Rossi G, Fiorino C, Bolognesi A, Di Muzio N. EP-1159: Hypofractionated adjuvant radiotherapy and concomitant trastuzumab for breast cancer: 5-year results. Radiother Oncol 2017. [DOI: 10.1016/s0167-8140(17)31595-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
29
|
Sini C, Fiorino C, Perna L, Noris Chiorda B, Sacco V, Pasetti M, Chiara A, Calandrino R, Di Muzio N, Cozzarini C. EP-1725: Predictors of diarrhea after whole-pelvis post-prostatectomy radiotherapy. Radiother Oncol 2016. [DOI: 10.1016/s0167-8140(16)32976-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
30
|
Chiara A, Fiorino C, Picchio M, Fodor A, Broggi S, Pasetti M, Incerti E, Mapelli P, Zerbetto F, De Antoni C, Azizi M, Calandrino R, Dell'Oca I, Di Muzio N. EP-1079: Clinical outcomes in locally advanced oropharyngeal cancer 18FDG PET-guided dose escalation IMRT-SIB. Radiother Oncol 2016. [DOI: 10.1016/s0167-8140(16)32329-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
31
|
Di Muzio NG, Fodor A, Noris Chiorda B, Broggi S, Mangili P, Valdagni R, Dell'Oca I, Pasetti M, Deantoni CL, Chiara A, Berardi G, Briganti A, Calandrino R, Cozzarini C, Fiorino C. Moderate Hypofractionation with Simultaneous Integrated Boost in Prostate Cancer: Long-term Results of a Phase I-II Study. Clin Oncol (R Coll Radiol) 2016; 28:490-500. [PMID: 26961088 DOI: 10.1016/j.clon.2016.02.005] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2015] [Revised: 01/18/2016] [Accepted: 01/19/2016] [Indexed: 10/22/2022]
Abstract
AIMS To report 5 year outcome and late toxicity in prostate cancer patients treated with image-guided tomotherapy with a moderate hypofractionated simultaneous integrated boost approach. MATERIALS AND METHODS In total, 211 prostate cancer patients, 78 low risk, 53 intermediate risk and 80 high risk were treated between 2005 and 2011. Intermediate- and high-risk patients received 51.8 Gy to pelvic lymph nodes and concomitant simultaneous integrated boost to prostate up to 74.2 Gy/28 fractions, whereas low-risk patients were treated to the prostate only with 71.4 Gy/28 fractions. Daily megavoltage computed tomography (MVCT) image guidance was applied. Androgen deprivation was prescribed for a median duration of 6 months for low-risk patients (for downsizing), 12 months for intermediate-risk and 36 months for high-risk patients. The 5 year biochemical relapse-free survival (bRFS), cancer-specific survival (CSS), overall survival and late gastrointestinal and genitourinary CTCAE.v3 toxicity were assessed. The effect of several clinical variables on both outcome and gastrointestinal/genitourinary toxicity was tested by uni- and multivariate Cox regression analyses. RESULTS After a median follow-up of 5 years, the late toxicity actuarial incidence was: genitourinary ≥ grade 2: 20.2%; genitourinary ≥ grade 3: 5.9%; gastrointestinal ≥ grade 2: 17%; gastrointestinal ≥ grade 3: 6.3% with lower prevalence at the last follow-up visit (≥ grade 3: genitourinary: 1.9%; gastrointestinal: 1.9%). Major predictors of ≥ grade 3 genitourinary and gastrointestinal late toxicity were genitourinary acute toxicity ≥ grade 2 (hazard ratio: 4.9) and previous surgery (hazard ratio: 3.4). The overall 5 year bRFS was 93.7% (low risk: 94.6%; intermediate risk: 96.2%; high risk: 91.1%), overall survival and CSS were 88.6% (low risk: 90.5%; intermediate risk: 87.4%; high risk: 87%) and 97.5% (low risk: 98.7%; intermediate risk: 95%; high risk: 94.3%), respectively. Risk classes and androgen deprivation were not significantly correlated with either bRFS, overall survival or CSS. Twelve patients experienced a biochemical relapse but none experienced clinically proven local and/or pelvic recurrence. CONCLUSION A satisfactory 5 year outcome with an acceptable toxicity profile was observed. The combination of image-guided radiotherapy-intensity-modulated radiotherapy, high equivalent 2 Gy dose (EQD2) with a moderate hypofractionated approach and extensive prophylactic lymph node irradiation also leads to very good outcome in high-risk patients.
Collapse
Affiliation(s)
- N G Di Muzio
- Department of Radiation Oncology, San Raffaele Scientific Institute, Milan, Italy.
| | - A Fodor
- Department of Radiation Oncology, San Raffaele Scientific Institute, Milan, Italy
| | - B Noris Chiorda
- Department of Radiation Oncology, San Raffaele Scientific Institute, Milan, Italy
| | - S Broggi
- Medical Physics, San Raffaele Scientific Institute, Milan, Italy
| | - P Mangili
- Medical Physics, San Raffaele Scientific Institute, Milan, Italy
| | - R Valdagni
- Fondazione IRCCS Istituto Nazionale dei Tumori, Radiotherapy, Milan, Italy
| | - I Dell'Oca
- Department of Radiation Oncology, San Raffaele Scientific Institute, Milan, Italy
| | - M Pasetti
- Department of Radiation Oncology, San Raffaele Scientific Institute, Milan, Italy
| | - C L Deantoni
- Department of Radiation Oncology, San Raffaele Scientific Institute, Milan, Italy
| | - A Chiara
- Department of Radiation Oncology, San Raffaele Scientific Institute, Milan, Italy
| | - G Berardi
- Department of Radiation Oncology, San Raffaele Scientific Institute, Milan, Italy
| | - A Briganti
- Department of Urology, San Raffaele Scientific Institute, Milan, Italy
| | - R Calandrino
- Medical Physics, San Raffaele Scientific Institute, Milan, Italy
| | - C Cozzarini
- Department of Radiation Oncology, San Raffaele Scientific Institute, Milan, Italy
| | - C Fiorino
- Medical Physics, San Raffaele Scientific Institute, Milan, Italy
| |
Collapse
|
32
|
Di Muzio N, Fodor A, Cozzarini C, Broggi S, Chiorda BN, Pasetti M, Briganti A, Valdagni R, Calandrino R, Fiorino C. Five-Year Outcomes and Late Toxicity in Prostate Cancer Patients Treated With Moderate Hypofractionated Helical Tomotherapy and Simultaneous Integrated Boost in a Phase 1-2 Study. Int J Radiat Oncol Biol Phys 2015. [DOI: 10.1016/j.ijrobp.2015.07.1094] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
33
|
Cozzarini C, Zuppardi F, Fiorino C, Briganti A, Fodor A, Naimo S, Noris Chiorda B, Pasetti M, Slim N, Suardi N, Sarno L, Montorsi F, Di Muzio N. OC-0321: Impact of urinary symptoms and incontinence on anxiety and depression 1 year after postprostatectomy radiotherapy. Radiother Oncol 2015. [DOI: 10.1016/s0167-8140(15)40319-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
34
|
Di Muzio N, Fodor A, Noris Chiorda B, Cozzarini C, Broggi S, Mangili P, Valdagni R, Dell'Oca I, Pasetti M, Deantoni C, Chiara A, Berardi G, Briganti A, Calandrino R, Fiorino C. PO-0719: Excellent 5 year outcome with image guided moderate hypofractionation in prostate cancer : phase I-II study results. Radiother Oncol 2015. [DOI: 10.1016/s0167-8140(15)40711-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
35
|
Tennant S, Simon R, Wang J, Pasetti M, Ernst R, Lees A, Galen J, Levine M. Bivalent vaccine strategies for invasive non-typhoidal Salmonella infections. Int J Infect Dis 2014. [DOI: 10.1016/j.ijid.2014.03.426] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
|
36
|
Noris Chiorda B, Cozzarini C, Fiorino C, Briganti A, Berardi G, Pasetti M, Sbalchiero A, Suardi N, Zerbetto F, Di Muzio N. PD-0306: Factors influencing urinary incontinence following post-prostatectomy IMRT irradiation. A prospective study. Radiother Oncol 2014. [DOI: 10.1016/s0167-8140(15)30411-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
37
|
Di Muzio N, Fiorino C, Fodor A, Noris Chiorda B, Berardi G, Cozzarini C, Pasetti M, Broggi S, Mangili P, Calandrino R. High-Dose Moderately Hypofractionated Tomotherapy for Prostate Cancer: 5-Year Results. Int J Radiat Oncol Biol Phys 2013. [DOI: 10.1016/j.ijrobp.2013.06.395] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
38
|
Simon R, Wang JY, Boyd MA, Tulapurkar ME, Ramachandran G, Tennant SM, Pasetti M, Galen JE, Levine MM. Sustained protection in mice immunized with fractional doses of Salmonella Enteritidis core and O polysaccharide-flagellin glycoconjugates. PLoS One 2013; 8:e64680. [PMID: 23741368 PMCID: PMC3669428 DOI: 10.1371/journal.pone.0064680] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2013] [Accepted: 04/17/2013] [Indexed: 11/26/2022] Open
Abstract
Non-typhoidal Salmonella (NTS) serovars S. Enteritidis and S. Typhimurium are a major cause of invasive bacterial disease (e.g., bacteremia, meningitis) in infants and young children in sub-Saharan Africa and also occasionally cause invasive disease in highly susceptible hosts (young infants, the elderly, and immunocompromised subjects) in industrialized countries. No licensed vaccines exist against human NTS infections. NTS core and O polysaccharide (COPS) and FliC (Phase 1 flagellin subunits) each constitute protective antigens in murine models. S. Enteritidis COPS conjugated to FliC represents a promising vaccine approach that elicits binding and opsonophagocytic antibodies and protects mice against lethal challenge with virulent S. Enteritidis. We examined the protective efficacy of fractional dosages of S. Enteritidis COPS:FliC conjugate vaccines in mice, and also established that protection can be passively transferred to naïve mice by administering sera from mice immunized with conjugate. Mice were immunized with three doses of either 10 µg, 2.5 µg (full dose), 0.25 µg, or 0.025 µg S. Enteritidis COPS:FliC conjugate at 28 day intervals. Antibody titers to COPS and FliC measured by ELISA fell consonant with progressively smaller vaccine dosage levels; anti-FliC IgG responses remained robust at fractional dosages for which anti-COPS serum IgG titers were decreased. Nevertheless, >90% protection against intraperitoneal challenge was observed in mice immunized with fractional dosages of conjugate that elicited diminished titers to both FliC and COPS. Passive transfer of immune sera from mice immunized with the highest dose of COPS:FliC to naïve mice was also protective, demonstrating the role of antibodies in mediating protection. These results provide important insights regarding the potency of Salmonella glycoconjugate vaccines that use flagellin as a carrier protein.
Collapse
Affiliation(s)
- Raphael Simon
- Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland, United States of America.
| | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Fodor A, Pasetti M, Fodor C, Mangili P, Rinaldin G, Dell'Oca I, Fiorino C, Calandrino R, Bolognesi A, Di Muzio N. PD-0316: Forward planned intensity modulated whole breast hypofractionated radiotherapy: results in 500 patients. Radiother Oncol 2013. [DOI: 10.1016/s0167-8140(15)32622-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
40
|
Dell'Oca I, Pasetti M, Cattaneo M, Fodor A, Berardi G, Noris Chiorda B, Perna L, Broggi S, Calandrino R, Di Muzio N. EP-1120: Stereotactic ablative radiotherapy for small lung tumors by means of TomoTherapy: preliminary results and toxicity. Radiother Oncol 2013. [DOI: 10.1016/s0167-8140(15)33426-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
41
|
Fodor A, Bolognesi A, Mangili P, Pasetti M, Fiorino C, Chiara A. 753 poster EARLY TOXICITY RESULTS OF A FORWARD PLANNED HYPOFRACTIONATED IMRT FOR WHOLE BREAST ADJUVANT TREATMENT. Radiother Oncol 2011. [DOI: 10.1016/s0167-8140(11)70875-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
42
|
Dell'Oca I, Fiorino C, Fodor A, Chiara A, Villa E, Casagrande W, Rognone A, Pasetti M, Broggi S, Busnardo E, Landoni C, Gianolli L, Calandrino R, Di Muzio N. 868 poster SIMULTANEOUS INTEGRATED BOOST 18FDG-PET BASED HELICAL TOMOTHERAPY IN RADICAL LOCALLY ADVANCED HEAD AND NECK CANCER. Radiother Oncol 2011. [DOI: 10.1016/s0167-8140(11)70990-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
43
|
Berardi G, Alongi F, Fiorino C, Pappalardi B, Pasetti M, Mangili P, Guazzoni G, Calandrino R, Di Muzio N. Hypofractionated Tomotherapy Treatment (HTT) in Prostate Cancer Lymph Nodal Relapse Detected by 11C-Choline PET/CT. Int J Radiat Oncol Biol Phys 2010. [DOI: 10.1016/j.ijrobp.2010.07.462] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
44
|
Dell'oca I, Fiorino C, Caimi M, Chiara A, Rognone A, Pasetti M, Broggi S, Landoni C, Calandrino R, Di Muzio N. Helical Tomotherapy with Simultaneous Integrated Boost 18FDG-Pet Based in Radical Locally Advanced Head and Neck Cancer. Int J Radiat Oncol Biol Phys 2009. [DOI: 10.1016/j.ijrobp.2009.07.929] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
45
|
Cozzarini C, Fiorino C, Alongi F, Berardi G, Bolognesi A, Broggi S, Deli A, Pasetti M, Rigatti P, Di Muzio N. Factors Predicting Late Severe Urinary Toxicity following Post-operative Irradiation for Prostate Carcinoma: A Single-institution Analysis of 742 Patients. Int J Radiat Oncol Biol Phys 2009. [DOI: 10.1016/j.ijrobp.2009.07.788] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
46
|
Ramirez K, Rodriguez L, Davis K, Galen J, Pasetti M. Su.41. Mucosal Salmonella Typhi Prime Followed by Parenteral Subunit Vaccine Boost Can Serve as an Effective Vaccine Strategy for Early Life Immunization. Clin Immunol 2008. [DOI: 10.1016/j.clim.2008.03.392] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
47
|
Magaly C, Pasetti M, Wang J, Thayil S, Arciniega-Martinez I, Rossini A, Levine M, Galen J. Su.38. Attenuated Salmonella Typhi Vaccine Strain CVD 908-htrA Used as a Live Vector Expressing Full-length Anthrax Protective Antigen in a Heterologous Prime-boost Regimen. Clin Immunol 2008. [DOI: 10.1016/j.clim.2008.03.389] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
48
|
Feng C, Rodriquez L, Davis K, Pasetti M. Co-delivery of lymphopoietic cytokines in live Salmonella vaccines enhances the T cell response (47.17). The Journal of Immunology 2007. [DOI: 10.4049/jimmunol.178.supp.47.17] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
Abstract
Live bacteria vaccine S. Typhi elicits strong mucosal and systemic immune responses. It is useful as a live vector to deliver heterologous antigens. Additionally, delivery of a eukaryotic expression vector by attenuated Salmonella leads to temporary expression of the coded gene in host cells after invasion. Because Salmonella invades preferentially macrophages and dendritic cells, the live bacteria could also be used to deliver immunomodulatory molecules to antigen-presenting cells. We hypothesize that co-delivery of lymphopoietic cytokine such as IL-2, IL-7 and IL-15, which has potential in promoting immune memory, enhances the efficacy of vaccination.
Murine IL-2, IL-7 and IL-15 were cloned into eukaryotic expression vector pCMS-EGFP, and introduced into S. Typhi(F1), which carries Y. pestis protective antigen F1. Mice were immunized intranasally with above derivative strains, and boosted with purified antigen F1 in alum adjuvant Alhydrogel.
This prime-boost strategy elicited strong mucosal and systemic antibody responses, as well as cell-mediated responses, e.g. antigen-specific proliferation and IFN-γ production of splenocytes. Inclusion of cytokine, however, further enhanced the cell-mediated responses. Antibody responses were not affected.
Our data strongly support our hypothesis that production of lymphopoietic cytokine during priming vaccination promotes memory T cell responses.
Collapse
Affiliation(s)
- Chiguang Feng
- Center for Vaccine Development, University of Maryland School of Medicine, Room 480, HSF I, 685 Baltimore St., Baltimore, Maryland, 21201
| | - Liliana Rodriquez
- Center for Vaccine Development, University of Maryland School of Medicine, Room 480, HSF I, 685 Baltimore St., Baltimore, Maryland, 21201
| | - Katherine Davis
- Center for Vaccine Development, University of Maryland School of Medicine, Room 480, HSF I, 685 Baltimore St., Baltimore, Maryland, 21201
| | - Marcela Pasetti
- Center for Vaccine Development, University of Maryland School of Medicine, Room 480, HSF I, 685 Baltimore St., Baltimore, Maryland, 21201
| |
Collapse
|
49
|
Motta M, Bolognesi A, Di Muzio N, Broggg S, Cattaneo G, Pasetti M, Politi L, Fazio F. 247 Critical appraisal of the management of a parasellar meningothelial meningioma. Radiother Oncol 2006. [DOI: 10.1016/s0167-8140(06)80724-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
50
|
Abstract
The Argentine vaccination schedule against diphtheria, tetanus and pertussis (DTP) recommends three doses of DTP vaccine at 2, 4 and 6 months of age, two boosters at 18 months and 6 years, a booster dose of tetanus vaccine every 10 years and two doses during pregnancy. To evaluate the effect of this schedule, antibodies against pertussis toxin (PT) and filamentous hemagglutinin (FHA) and against tetanus and diphtheria toxoids were determined by ELISA in serum samples from children (1 month to 6 years) who received different doses of DPT vaccine: 0 dose (n = 50), 1 dose (n = 25), 2 doses (n = 25), 3 doses (n = 55), first and second booster (n = 25); 25 pregnant women and their offspring, and 45 adults. High antibody levels against PT (> 140 EU/ml) and FHA (> 80 EU/ml) were recorded in mothers and in the newborn. Antibody titers against PT increased with the number of doses given and decreased with time. Full protection against tetanus (titers > 0.1 IU/ml) was observed in the group of adults (0.37 IU/ml), in mothers (4.4 IU/ml) and their newborn offspring (5.5 IU/ml), and in children after receiving the second dose of DTP vaccine (1.86 IU/ml). The immune status for diphtheria was far lower, as most of the groups lacked adequate protection. After the third dose of DTP vaccine, only 78% of the children had antibody titers above the protective level (0.1 IU/ml). Since antibody levels considered to provide full protection were only achieved after the first booster dose of DTP vaccine, the primary three-dose schedule seems to be insufficient to confer adequate immunity in all vaccinees. Because of the high proportion of non-protected adults, a booster dose of Td vaccine should be considered for this group.
Collapse
Affiliation(s)
- M Pasetti
- IDEHU, Instituto de Estudios de la Inmunidad Humoral (CONICET-UBA), Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Argentina
| | | | | | | |
Collapse
|